CYP2D6与他莫昔芬活性代谢物:致敬David A. Flockhart
本期CPT刊载CPIC关于用CYP2D6基因分型指导乳腺癌他莫昔芬治疗的指南。CYP2D6将他莫昔芬代谢为活性更强的代谢物endoxifen,CYP2D6活性降低者循环endoxifen浓度降低。本文致敬已故David Flockhart博士,其早期基础发现促成了该指南。
要点
- CYP2D6将他莫昔芬代谢为活性更强的endoxifen。
- CYP2D6活性降低者循环endoxifen浓度降低。
- CPIC发布CYP2D6基因分型指导他莫昔芬治疗的指南。
核心结论
- CYP2D6活性降低的患者循环endoxifen浓度降低,CPIC据此发布CYP2D6基因分型指导他莫昔芬治疗的指南。
主要发现
- CYP2D6催化他莫昔芬代谢为活性更强的代谢物endoxifen。
- CYP2D6活性降低的患者循环endoxifen浓度降低。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This issue of Clinical Pharmacology & Therapeutics (CPT) includes the Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for using CYP2D6 genotyping to guide tamoxifen therapy for breast cancer patients. CYP2D6 metabolizes tamoxifen to its more active metabolite, endoxifen, and patients with reduced CYP2D6 activity have reduced circulating endoxifen concentrations. In this associated commentary, we recognize and honor the late Dr. David Flockhart, who began the research and made early fundamental discoveries on tamoxifen that have now resulted in this guideline.
引用
- Skaar TC, Desta Z. CYP2D6 and Endoxifen in Tamoxifen Therapy: A Tribute to David A. Flockhart. Clin Pharmacol Ther. 2018. PMID: 29473149. doi:10.1002/cpt.1039
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。